// App-Quantinova.ai

: Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER).

Researchers

Presenter

  • Andrea Necchi

Principal Investigators

  • Roberto Iacovelli

  • Massimo Di Maio

  • Paolo Gontero

  • Petra Fettes

  • Kathrin Klar

  • Frank Hermann

  • Eugen Leo

Medical Centers

  • Vita-Salute University, IRCCS San Raffaele Hospital, Milan, Italy

  • Catalym GmbH, Planegg-Martinsried, Germany

  • Oncology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Catholic University of Rome, Rome, Italy

  • Dipartimento di Discipline Medico Chirurgiche, Clinica Urologica, University of Torino, Torino, Italy

  • Department of Oncology, University of Turin - Ordine Mauriziano Hospital, Turin, Italy

Locations

  • Italy

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Programmed death-ligand 1

  • Growth differentiation factor 15

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved